Lumos secures additional US Medicare reimbursement coverage for FebriDx®
23 April 2025
Lumos has announced that it has received confirmation of Medicare reimbursement coverage from two additional Medicare Administrative Contractors (MACs), First Coast Service Options (FCSO) and Noridian Healthcare Solutions (Noridian), retroactive from 1 April 2025.
With the addition of these two MACs, Lumos now has Medicare reimbursement from four of the seven MACs, representing over 55% of the total US Medicare payment coverage.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“Securing additional Medicare coverage from FCSO and Noridian for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.”
“Lumos remains committed to securing adoption from the remaining three MACs and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
Click to read the ASX release.
With the addition of these two MACs, Lumos now has Medicare reimbursement from four of the seven MACs, representing over 55% of the total US Medicare payment coverage.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“Securing additional Medicare coverage from FCSO and Noridian for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.”
“Lumos remains committed to securing adoption from the remaining three MACs and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
Click to read the ASX release.
